On 27 March 2024, Biocon announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved its liraglutide in the UK, which is the first approved biosimilar to Novo Nordisk’s Victoza® (liraglutide). Biocon’s liraglutide, a drug-device combination (6mg/ml solution for injection in pre-filled pen) used to treat Type 2 Diabetes, was filed and will be marketed in the UK by its European partner, Zentiva.
This follows the Indian launch of a liraglutide biosimilar, Glenmark’s Lirafit®, in January this year.